$RPRX · Royalty Pharma plc
Royalty Pharma's Q3 FY2026 10-Q shows total income and other revenues of $690.1M, up 13.3% YoY, with income from financial royalty assets of $647.6M. Net income attributable to Royalty Pharma plc fell to $144.7M ($0.32 diluted EPS) from $284.2M ($0.66) a year ago. The decline was driven by a $150.4M financial royalty asset impairment and $45.6M in losses on equity securities.
- Q3 revenue $690.1M, +13.3% YoY; nine-month revenue $1.99B, +13.6%
- Net income attributable to Royalty Pharma plc $144.7M vs $284.2M a year ago
- Diluted EPS $0.32 vs $0.66 in Q3 2025
- Financial royalty asset impairment $150.4M in Q3, $219.8M year-to-date
- Losses on equity securities $45.6M in Q3
Shares are down 0.18% to $66.40 in regular trading, roughly flat on the day, suggesting the impairment-driven earnings decline was largely anticipated or offset by solid revenue growth.
N/A
Royalty Pharma's revenue growth contrasts with the impairment charges, reflecting the mixed nature of royalty portfolios where top-line diversification can coexist with concentrated asset writedowns.
The $150.4M Q3 impairment and $219.8M year-to-date writedown highlight concentration risk in specific royalty assets; equity security losses of $45.6M add mark-to-market volatility.